Navigation Links
Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Date:2/5/2008

al is to assess the safety, tolerability and pharmacokinetic parameters of a single dose of AZ-007. Using a double blind, randomized, dose-escalation trial design, four doses of AZ-007 (ranging from 0.5 to 4.0 mg) will be compared to placebo.

About Insomnia

Insomnia is a prevalent disorder that drives almost $5 billion in worldwide sales of prescription medications each year, with about 10 to 30% of the U.S. population experiencing either chronic or occasional insomnia. In a large survey conducted by the National Sleep Foundation in 2005, results showed that 54% of the respondents experienced a minimum of one symptom of insomnia at least a few nights a week. Of those, respondents complained primarily of waking up feeling unrefreshed (38%), waking up frequently during the night (32%), having difficulty falling asleep (21%), and waking up too early and not being able to get back to sleep (21%). There is a potentially significant clinical need for rapid and predictable onset of sleep in patients with insomnia, coupled with a predictable duration of sleep and rapid, clear awakening.

About AZ-007 (Staccato zaleplon)

AZ-007 is the combination of Alexza's proprietary Staccato system with zaleplon, a drug belonging to the class of compounds known generally as non-benzodiazepine hypnotics. The Staccato system technology is a hand-held, chemically-heated, single dose inhaler designed to generate and deliver excipient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics.

The Company believes that AZ-007's unique delivery via the Staccato system may provide rapid sleep onset. Moreover, coupling the short half-life and short duration of effect of zaleplon, with a lower dose enabled by the Staccato system technology, the overall product profile may match well with an unmet clinical need for patients with insomnia.

Clinical Pipeline Development Status

-- AZ-004 (Staccato loxapine) is initially bein
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Ceregene, Inc. today announced additional ... double-blind, randomized, controlled Phase 2b clinical study of ... designed to deliver the neurotrophic factor neurturin, for ... robust response to CERE-120 in Parkinson,s patients diagnosed ... those diagnosed 10 years or more (p<.005), as ...
(Date:5/20/2013)... , May 21, 2013 ... Assembly, where world,s health ministers gather to address the ... Mental and neurological disorders (MNDs) affect 700 million ... non-communicable disease (NCD) burden ,Do You Mind?, ... the role each can play to collectively address MNDs ...
(Date:5/20/2013)... May 20, 2013 The Board of ... companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, ... Board.  Guy Mayer , an ... of the Board of Directors and David Johnson, an ... director. Before joining OSI as Board ...
Breaking Medicine Technology:Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 3
... Medical Receives European CE Mark Approvals for Drug Eluting Balloon... -- HELMOND, The Netherlands, November 16, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... The largest natural allograft available on the market today ... The Musculoskeletal Transplant Foundation (MTF), the nation,s leading provider of ... cm sized grafts of FlexHD®, their hydrated acellular dermal matrix, ...   These two new sizes are the largest ...
Cached Medicine Technology:Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 2Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 3Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 4Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 5Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 6Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 7Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 8Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF 2
(Date:5/21/2013)... The National Resident Matching Program NRMP® ... its Board of Directors. Hal B. Jenson, M.D., ... of Medicine, has been named President. Maria C. ... of California San Diego, is the President-Designate, and Glenn ... Medical Center, is the Secretary-Treasurer. Kenneth B. Simons, ...
(Date:5/21/2013)... Dr. James C. Wittig, Chief of ... Sarcoma Division of the John Theurer Cancer Center at ... named one of the top 13 Orthopedic Oncologists in ... Wittig is one of approximately 125 surgeons in America ... by surveying thought leaders in the field of Oncology. ...
(Date:5/21/2013)... 21, 2013 Brunswick Laboratories, Inc. ... the development and standardization of validated analytical methods, ... Brunswick Laboratories and the USDA, as a First ... This decision comes after extensive review by an ... Harnly of the U.S. Department of Agriculture. , ...
(Date:5/21/2013)... According to the Center for Disease Control and ... year. Over 800,000 of these bites require medical attention, ... should be aware of the danger that dog bites pose ... and children may sustain more serious injuries than an adult. ... the ages of 5 and 9 are at the greatest ...
(Date:5/20/2013)... USA Book News announced Monday that "The ... won the top honor in its 2013 International Book ... multitude of international titles published from 2011-2013, "The Infinity ... both mainstream and new age audiences looking to improve ... , “The Infinity Zone” is a phenomenon ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:AOAC International Approves ORAC as First Action Official Method 2Health News:Personal Injury Law Firm Announces New Informational Graphic Regarding Dog Bite Injuries 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3
... 19 PAREXEL International Corporation (Nasdaq: PRXL ) ... Monday, January 26, 2009 after the close of the stock ... at www.parexel.com and on the PR Newswire website ... live webcast at 10:00 a.m. ET on Tuesday, January 27, ...
... a free prostate cancer screening and educational information on Monday 1/19 ... providing Atlanta residents with information about prostate health, the Prostate Proactivity ... (RCOG) and NewsTalk 750 WSB. , ... Atlanta, GA ...
... A collection of hospitals in eight cities around the ... surgical checklist during major operations can lower the incidence of ... study was led by researchers from the Harvard School of ... and the results are published Online First on Wednesday, January ...
... Believe in Khanna LASIK and change (improve) vision especially if you ... ... 18, 2009 -- In honor of the Presidential Inauguration on Tuesday, ... free LASIK surgery to any US citizen named "Barack Hussein Obama". ...
... Takes only minutes when temperatures drop to cause permanent damage, ... -- When the weather outside is frigid, do you know ... minutes for exposed skin to become frostbitten if the temperature ... at 20 miles per hour or more," Dr. Taizoon Baxamusa, ...
... the HIMSS Analytics Database, 85 percent of hospitals in the contracting phase ... since November 2007, when CCHIT released its first acute care or inpatient ... ... data from the HIMSS Analytics Database, 85 percent of hospitals in the ...
Cached Medicine News:Health News:PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2Health News:Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity 2Health News:Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 4Health News:LASIK Surgery for "Barack Hussein Obama" 2Health News:Hard, Cold Facts About Frostbite 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 3Health News:85 Percent of Hospitals Select CCHIT Certified Products 4Health News:85 Percent of Hospitals Select CCHIT Certified Products 5
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: